Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: IsatuximabDrug: Dexamethasone or equivalentDrug: FludarabineDrug: CytarabineDrug: Liposomal daunorubicinDrug: Daunorubicin (nonliposomal)Drug: IdarubicinDrug: Filgrastim or equivalentDrug: MitoxantroneDrug: DoxorubicinDrug: VincristineDrug: Pegaspargase (PEG) AsparaginaseDrug: CyclophosphamideDrug: EtoposideDrug: MethotrexateDrug: L - AsparginaseDrug: HydroxyureaDrug: L - Asparaginase (Erwinase)
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 67
- Registration Number
- NCT03860844
- Locations
- 🇺🇸
Children's Medical Center of Dallas-Site Number:8400002, Dallas, Texas, United States
🇲🇽Investigational Site Number :4840001, Monterrey, Nuevo León, Mexico
🇧🇷Investigational Site Number :0760007, Porto Alegre, Rio Grande Do Sul, Brazil
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT03850535
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-01-26
- Target Recruit Count
- 118
- Registration Number
- NCT03837873
- Locations
- 🇨🇳
the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳the First Affiliated Hospital of Jilin University, Changchun, Jilin, China
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 181
- Registration Number
- NCT03836209
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 21
- Registration Number
- NCT03826992
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT03813147
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇺🇸Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT03808610
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood
- Conditions
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 65
- Registration Number
- NCT03793478
- Locations
- 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
- Conditions
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 12
- Registration Number
- NCT03792256
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 142
- Registration Number
- NCT03765541
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷CHU de Limoges, Limoges, France
🇫🇷CHU de Bordeaux, Pessac, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.